Sionna Therapeutics Q2 net loss widens - SION News | RalliesSionna Therapeutics Q2 net loss widens
S
SION• Analyst coverage
- The current average analyst rating on the shares is buy.
- The breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell".
- The average consensus recommendation for the biotechnology & medical research peer group is buy.
- Wall Street's median 12-month price target for Sionna Therapeutics, Inc. is $54.00, about 14.1% above its August 5 closing price of $47.34.
Expense drivers and cash outlook
- The company said increased R&D expenses were mainly driven by development costs to advance its clinical pipeline.
- Higher operating expenses were also partly due to personnel-related costs, including stock-based compensation.
- Sionna said it expects its cash position to fund operations into 2028.
Q2 loss widens as operating expenses rise
- Sionna Therapeutics said its Q2 net loss increased year over year.
•
